Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders. Approximately one‐third of the patients with MDD are treatment resistant to the current antidepressants. There is also a significant therapeutic time lag of weeks to months. Furthermore, depression in patients with b...

Full description

Saved in:

Bibliographic Details
Published in:	Psychiatry and clinical neurosciences Vol. 73; no. 10; pp. 613 - 627
Main Author:	Hashimoto, Kenji
Format:	Journal Article
Language:	English
Published:	Melbourne John Wiley & Sons Australia, Ltd 01.10.2019 Wiley Subscription Services, Inc
Subjects:	(R)‐ketamine (or arketamine), (S)‐ketamine (or esketamine), (S)‐norketamine Animal models Animals Antagonists Antidepressants Antidepressive Agents - administration & dosage Antidepressive Agents - history Antidepressive Agents - pharmacology Bipolar disorder Bipolar Disorder - drug therapy Calcium Calcium channels (voltage-gated) Depressive Disorder, Major - physiopathology Enantiomers Excitatory Amino Acid Antagonists - administration & dosage Excitatory Amino Acid Antagonists - history Excitatory Amino Acid Antagonists - pharmacology Glutamic acid receptors gut microbiota History, 20th Century History, 21st Century Humans Ketamine Ketamine - administration & dosage Ketamine - analogs & derivatives Ketamine - history Ketamine - pharmacology Mental depression Mental disorders Metabolites N-Methyl-D-aspartic acid receptors Patients PCN Frontier Review PCN Frontier Reviews Potassium channels (inwardly-rectifying) Potassium channels (voltage-gated) Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors γ-Aminobutyric acid A receptors (R)-ketamine (or arketamine), (S)-ketamine (or esketamine), (S)-norketamine gut microbiota
ISSN:	1323-1316, 1440-1819, 1440-1819
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!